Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch Health Companies Inc.

www.bauschhealth.com

Latest From Bausch Health Companies Inc.

Sole US Patent Protecting Apriso Mesalamine Capsules Is Obvious

In a ruling favouring Mylan, GeneriCo and Flat Line Capital, The US Court of Appeals has confirmed an inter partes review finding that key claims of the sole patent listed against Bausch Health’s Apriso mesalamine brand are unpatentable as obvious.

 


Intellectual Property Gastrointestinal

Lumify Ad Launches As Bausch Spends More Behind OTC Eye Care Brands

Following first anniversary of Lumify launch, "we're still in a pretty heavy investment period supporting trial because our data suggest that when people use the product, they persist in using the product. And so for now, we got our foot down on of the promotional side," says CFO Paul Herendeen.

OTC Drugs Commercial

Reimagining IT: Bausch Health Puts Customers First In Planning For A Data-Driven Future

Information is the lifeblood that sustains drug development – but the ability to disperse, differentiate and make sense of it is what delivers success in the marketplace. Bausch Health Companies has decided to make global alignment through the strategic application of IT the centerpiece of its effort to shed the legacy of its acquisitive predecessor Valeant Pharmaceuticals. 

Business Strategies C-Suite Speaks

First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.

Clinical Trials Dermatology
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register